Nektar Therapeutics (LTS:0UNL) Cyclically Adjusted Book per Share: $59.39 (As of Mar. 2026)


LTS:0UNL Nektar Therapeutics LTS:0UNL
50 GF Score
Price $73.76
GF Value $6.00
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

Nektar Therapeutics LTS:0UNL -4.01% 50 Cyclically Adjusted Book per Share is $59.39 as of Mar. 2026. GuruFocus rates LTS:0UNL with a GF Score™ of 50/100 and a GF Value™ of $6.00 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $19.551. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $59.39 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 3.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.40% per year. And the median was 1.30% per year.

As of today (2026-07-09), Nektar Therapeutics's current stock price is $73.76. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $59.39. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 1.24.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.88.


Nektar Therapeutics  (LTS:0UNL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=73.76/59.39
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 5.88.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.99 51.08 56.07 57.50 59.20

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.31 28.70 60.69 59.20 59.39

LTS:0UNL vs OCUL, PVLA, GENB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


LTS:0UNL
50GF Score
Nektar Therapeutics LTS:0UNL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.551/330.2130*330.2130
=19.551

Current CPI (Mar. 2026) = 330.2130.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -4.310 241.018 -5.905
201609 -7.387 241.428 -10.104
201612 8.628 241.432 11.801
201703 4.338 243.801 5.876
201706 0.326 244.955 0.439
201709 8.043 246.819 10.761
201712 8.258 246.524 11.061
201803 5.384 249.554 7.124
201806 161.860 251.989 212.106
201809 155.164 252.439 202.969
201812 148.464 251.233 195.137
201903 140.638 254.202 182.691
201906 133.501 256.143 172.106
201909 127.034 256.759 163.376
201912 119.435 256.974 153.475
202003 109.329 258.115 139.867
202006 105.380 257.797 134.982
202009 97.908 260.280 124.214
202012 89.730 260.474 113.754
202103 81.832 264.877 102.017
202106 73.863 271.696 89.771
202109 65.145 274.310 78.421
202112 54.954 278.802 65.088
202203 48.952 287.504 56.224
202206 36.716 296.311 40.917
202209 32.899 296.808 36.602
202212 29.165 296.797 32.449
202303 19.092 301.836 20.887
202306 15.539 305.109 16.818
202309 12.531 307.789 13.444
202312 10.266 306.746 11.051
202403 10.350 312.332 10.943
202406 6.494 314.175 6.826
202409 3.975 315.301 4.163
202412 4.904 315.605 5.131
202503 1.107 319.799 1.143
202506 -1.944 322.561 -1.990
202509 4.329 324.800 4.401
202512 4.408 324.054 4.492
202603 19.551 330.213 19.551

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $59.39 mean?
Nektar Therapeutics (LTS:0UNL) has a Cyclically Adjusted Book per Share of $59.39 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Cyclically Adjusted Book per Share too high?
Nektar Therapeutics' current Cyclically Adjusted Book per Share is $59.39. Overall, Nektar Therapeutics has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Cyclically Adjusted Book per Share compare to OCUL and PVLA?
Nektar Therapeutics' Cyclically Adjusted Book per Share of $59.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Cyclically Adjusted Book per Share is $59.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (LTS:0UNL) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.00, compared to a current price of $73.76 — trading 1129.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is $59.39. Nektar Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nektar Therapeutics (LTS:0UNL), the current Cyclically Adjusted Book per Share is $59.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (LTS:0UNL) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of $73.76 is trading 1129.3% above its estimated GF Value™ of $6.00. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for LTS:0UNL:

  • Cyclically Adjusted Book per Share: $59.39
  • GF Value™: $6.00 vs. price of $73.76 (1129.3% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the LTS:0UNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nektar Therapeutics Business Description

Other Exchanges NKTR:USAITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
50GF Score

Get the complete analysis for LTS:0UNL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$73.76
Price
$6.00
GF Value